BELLUS Health (BLU) Stock Analysis
NASDAQHealthcareBiotechnology
What BELLUS Health does
BELLUS Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, and founded in 1993. The firm focuses on developing therapeutic solutions for refractory chronic cough (RCC) and other related cough hypersensitivity conditions. Its leading product candidate, BLU-5937, an antagonist designed to block the P2X3 receptor, is currently progressing through Phase II clinical trials for the treatment of both RCC and chronic pruritus.
Key metrics
ETFs linked to BLU
Broad-market and Healthcare sector ETFs an investor holding BELLUS Health is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how BLU fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze BLU in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for BELLUS Health?
- BELLUS Health trades under the ticker BLU on NASDAQ.
- Which exchange is BLU listed on?
- BLU is listed on NASDAQ.
- What sector does BELLUS Health operate in?
- BELLUS Health is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze BLU in a portfolio?
- PortView shows BLU's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.